No Seasonal Accumulation of Resistant P. falciparum when High-Dose Chloroquine Is Used by Ursing, Johan et al.
No Seasonal Accumulation of Resistant P. falciparum
when High-Dose Chloroquine Is Used
Johan Ursing
1,2*, Poul-Erik Kofoed
2,3,4, Amabelia Rodrigues
2, Lars Rombo
1,5,6
1Malaria Research, Department of Infectious Diseases, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden, 2Projecto de Sau ´de de Bandim, Indepth Network,
Bissau, Guinea-Bissau, 3Department of Paediatrics, Kolding Hospital, Kolding, Denmark, 4Research Initiative of Health Services, Kolding Hospital, Kolding, Denmark,
5Department of Infectious Diseases, Ma ¨larsjukhuset, Eskilstuna, Sweden, 6Center for Clinical Research, Sormland County Council, Eskilstuna, Sweden
Abstract
Background: Potentially chloroquine resistant P. falciparum, identified by the 76T haplotype in the chloroquine resistance
transporter (pfcrt 76T), are highly prevalent throughout Africa. In Guinea-Bissau, normal and double dose chloroquine have
respective efficacies of 34% and 78% against P.falciparum with pfcrt 76T and approximately three times the normal dose of
chloroquine is routinely taken. Proportions of pfcrt 76T generally increase during high transmission seasons, as P.falciparum
with pfcrt 76T commonly survive treatment with normal dose chloroquine. In Guinea-Bissau, there should be no seasonal
increase of pfcrt 76T if the high doses of CQ commonly used are effective.
Methods and Findings: P. falciparum parasite density, age, sex, the proportion of chloroquine resistance associated
haplotypes pfcrt 76T and P. falciparum multidrug resistance gene 1 86Y were assessed in 988 samples collected from children
between 2002 and 2007. There was no seasonal accumulation of any allele. During the high and low transmission periods
the pfcrt 76T proportions were 24% (95% CI, 21–27%) and 26% (95% CI, 20–33%). There was no significant change of pfcrt
76T (OR 1.05, 95% CI; 0.94–1.16 p=0.39) or pfmdr1 86Y (OR 0.92, 95%CI; 0.83–1.01 p=0.08) proportions between 2003 and
2007. Lower median parasite density (P.falciparum/ml) was associated with pfcrt 76T (15254 [95% CI, 12737–17772]; n=164)
compared to pfcrt 76K (18664 [95% CI, 16676–20653]; p=0.003; n=591). Similarly, pfmdr1 86Y was associated with a lower
median parasite density (16320 [95% CI, 13696–18944]; n=224) compared to pfmdr1 86N, (18880 [95% CI, 16701–21059];
P=0.018; n=445).
Conclusions: In contrast to the rest of Africa, P. falciparum parasites resistant to normal dose chloroquine do not have a
selective advantage great enough to become the dominant P.falciparum type in Guinea-Bissau. This is most likely due to the
efficacy of high-dose chloroquine as used in Guinea-Bissau, combined with a loss of fitness associated with pfcrt 76T.
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Introduction
Chloroquine resistant (CQR) Plasmodium falciparum spread
through Africa during the 80’s and 90’s and was first described
in Guinea-Bissau in 1990 [1]. Until June 2008 chloroquine (CQ)
remained, by far, the most commonly used antimalarial in the
country. In Guinea-Bissau, as in most other areas of Africa, CQR
is associated with a mutation in the CQR transporter (pfcrt K76T)
[2,3]. Despite the presence of the pfcrt 76T mutation and
continued CQ use that should select CQR P. falciparum, the
prevalence of CQR P. falciparum is exceptionally low and
unchanged in Guinea-Bissau [4].
The median CQ doses prescribed and reportedly taken in
Guinea-Bissau were 81 and 77 mgkg
21, divided into 2–3 doses per
day for median 5 days [5]. According to local physicians, CQ has
always been prescribed in this way and use of high doses has been
recorded since 1994 [4]. We have shown that 50 mgkg
21 of CQ in
2 divided daily doses over 3 days resulted in a 92% PCR corrected
efficacy at day 28 [6] whereas treatment with the standard dose of
25 mgkg
21 given during 3 days had an 80% efficacy [6]. In
addition, when treating P. falciparum carrying the CQR associated
genetic marker (pfcrt 76T), 50 mgkg
21 had a 78% efficacy whilst
only 34% were successfully treated with 25 mgkg
21 [2].
The marked reduction of the pfcrt 76T haplotype in Malawi
following the withdrawal of CQ [7] suggests that pfcrt 76T
identifies a less fit parasite than pfcrt 76K in the absence of CQ. In
line with that, CQ resistance has been shown to be an energy
dependent process [8]. Studies from Sudan and The Gambia
reported increasing pfcrt 76T haplotype prevalence during the high
transmission season and decreasing during the low transmission
season [9,10]. The probable explanation is that pfcrt 76T carrying
parasites survive treatment with standard CQ doses, thereby
accumulating during the high transmission season when CQ is
frequently used. When less CQ is used during the low transmission
season, haplotype prevalences are reversed because of better
fitness of the 76K haplotype in the absence of CQ.
If the high dose CQ treatment commonly used in Guinea-
Bissau is efficacious as our data suggests, pfcrt 76T carrying
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6866parasites will lose much of their survival advantage and therefore
not accumulate markedly during the high transmission season. To
evaluate this hypothesis we have analysed seasonal variations of
the proportions of pfcrt 76K and 76T and pfmdr1 86N and 86Y in
Guinea-Bissau.
Methods
The studies were conducted at the Bandim Health Project in
Bissau, Guinea-Bissau. The Bandim Health Project is a Demo-
graphic Survey Site (DSS) covering approximately 16 km
2, mainly
comprising semi-urban areas. The population is approximately 90
000 including about 12 000 children ,5 years of age. Three
primary health care centres, Bandim, Belem and Cuntum serve
the population. In addition, the national hospital with 125 beds
5 km away, also serves as a primary contact as well as a referral
hospital for patients.
Children develop symptomatic P. falciparum malaria infections
all the year round in Guinea Bissau. However, there is a distinct
seasonality with higher incidence of malaria between May and
December just before, during and after the rainy season that lasts
from May/June to October/November. The malaria prevalence
has decreased over the years. In 1990, 183/312 (59%) of children
(aged 3–6 yrs) had P. falciparum in community surveys during the
rainy season compared to, 7/197 (3.6%) of children (aged,5 yrs)
in 2004 [11].
Since October 2002 (except for Oct 2006) three clinical trials
including collection of blood spotted onto filter-papers at day 0 for
genotyping have been conducted back to back at Bandim Health
Centre. From November 2006 until December 2008 the last study
also recruited patients from Belem and Cuntum health centres.
Inclusion criteria were similar in all studies requiring microscop-
ically verified malaria (.20 P. falciparum per 200 white blood cells)
with fever (or history of fever in the past 24 hours) in the absence
of signs of severe malaria (convulsions, severe anaemia, hyper-
parasitaemia, clinically poor condition).
Following informed consent a total of 988 (501 boys and 486
girls) children were included between October 2002 and
December 2007. The total number of inclusions each month
between January and December were 78, 49, 32, 32, 71, 118, 93,
66, 58, 137, 147, 107. We designated January – April as the low
transmission season and May to December as the high
transmission season. The high transmission season was split into
early (May-August) and late (September-December) high trans-
mission season. This split is halfway through the season and also at
the point of lowest number of new cases during the high
transmission season.
Pfcrt K76T, pfmdr1 N86Y, pfmsp1 and pfmsp2 were identified
using previously described PCR based methods [12,13]. PCR and
restriction products were resolved on 2% agarose gels (Amresco,
Solon, OH). All gels were stained with ethidium bromide and
visualized under UV transillumination (BioRad GelDoc System,
BioRad, Hercules, CA).
Monthly rainfall data from 2003 to 2007 was provided by the
National Meteorological Service and are presented as mean
monthly values for the whole period.
Ethical approval was given by the Ministe ´rio da Sau ´dePu ´blica in
Guinea-Bissau (019/DHE/2004 and 030/DHE/2004 and 064/
DGSP/2006), Karolinska Institute in Stockholm, Sweden (2005/
111-31/1, 2009/881-31/4 and 2006/1151-31/1), and the Central
Ethical Committee in Denmark (624-01-0042 and 2004-7041-11).
The studies were registered at ClinicalTrials.gov (https://register.
clinicaltrials.gov/) with the study IDs PSB-2001-chl-amo,
NCT00137514 and PSB-2004-paracetamol, NCT00137566 and
PSB-2006-coartem NCT00426439.
Age and parasite density over the years 2002–2007 were
compared using the non-parametric test for trend. Genotyping
data from October 2002 to December 2007 were pooled and
monthly proportions of pfcrt 76K and 76T and pfmdr1 86N and
86Y were calculated. Changes in allele proportions by month or
year were assessed using logistic regression. Because children were
not recruited into the study throughout the year 2002, only data
from 2003–2007 were used to assess any trend of changing annual
haplotype proportion. Variations of parasite density were assessed
by quantile regression using bootstrapping with 1000 repetitions.
Haplotypes were analysed as 3 groups (76T, 76K or both for pfcrt
and 86Y, 86N or both for pfmdr1). The association between pfmsp
families and pfcrt and pfmdr1 haplotypes were assessed using Fishers
exact test.
Results
Study population
The median age was 65 months, the inter-quartile range (IQR)
was 38-105 months and the median parasitaemia was 15600 (IQR
6800-38400) P. falciparum per micro-litre assuming a white blood
cell count of 8000 per micro-litre (Table 1).
Stable proportions of pfcrt 76K and 76T and pfmdr1 86N
and 86Y during the year
Pfcrt 76K and 76T alleles were successfully identified in 954/988
samples and pfmdr1 86N and 86Y alleles in 958/988. If both alleles
were identified at one locus both were included as numerators but
only counted as one in the denominator.
There was no continuous monthly trend of changing pfcrt 76T
or 76K (figure 1) nor pfmdr1 86Y or 86N (figure 2) allele
proportions during the high (May-December) or the low
Table 1. Age, sex and parasitaemia by year.
Year 2002 2003 2004 2005 2006 2007 P(trend)
Nr. of children 103 333 158 171 115 108
Sex male:female 57:46 155:178 83:74
* 85:86 62:53 58:49
Age in months 68 (34–117) 71 (40–108)
$ 60 (36–105) 64 (38–94) 64 (43–96) 60 (38–90) 0.07
P. falciparum per ml blood 14000 (7600–17200) 14400 (6400–18600) 16100 (4000–40000) 25000 (5520–40000) 34188 (11560–66667) 20000 (7970–66667) ,0.001
$age missing for 4 children,
*sex unknown for one child.
Age and parasitaemia are presented as median values with interquartile ranges in brackets.
Data from 2002 is not included in presented p-values but inclusion of 2002 did not significantly alter the results.
doi:10.1371/journal.pone.0006866.t001
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proportions during the high and low transmission periods were
186/777 (24% [95% CI, 0.21–0.27]) and 46/177 (26% [95%
CI, 0.20–0.33]), respectively. The total pfcrt 76K proportions
were 621/777 (80% [95% CI, 0.77–0.83]) and 140/177 (79%
[95% CI, 0.73–0.85]), respectively. The total pfmdr1 86Y
proportions were 338/779 (43%) and 79/179 (44%), respec-
tively. The total pfmdr1 86N proportions were 562/779 (72%)
and 131/179 (73%), respectively. There were no significant
differences.
Figure 1. Monthly variation of pfcrt K76T haplotypes amongst children presenting with uncomplicated P. falciparum malaria
between October 2002 and December 2007. Mean haplotype prevalence were calculated from samples collected continuously between
October 2002 and December 2007. Binomial exact 95% confidence intervals are presented as range spikes with caps.
doi:10.1371/journal.pone.0006866.g001
Figure 2. Monthly variation of pfmdr1 86N and 86Y haplotypes amongst children presenting with uncomplicated P. falciparum
malaria between October 2002 and December 2007. Binomial exact 95% confidence intervals are presented as range spikes with caps.
doi:10.1371/journal.pone.0006866.g002
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minor fluctuations. From February to May there was a monthly
decrease in the pfcrt 76T proportion (OR, 0.74 [95% CI, 0.56–
0.98]; p=0.04), whilst the pfcrt 76K proportion increased (OR,
1.65 [1.20–2.29]; p=0.002) per month. From May to July there
was a monthly increase of the pfcrt 76T proportion (OR, 1.43
[95% CI, 0.99–2.06]; p=0.06), whilst the pfcrt 76K proportion
decreased (OR, 0.59 [95% CI, 0.39–0.88]; p=0.01) per month.
There were similar but opposite trends from July to September but
the changes were not significant.
Proportions of alleles pfcrt 76K and 76T and pfmdr1 86N
and 86Y between 2003 and 2007
>For each of the years 2003–2007 pfcrt K76T and pfmdr1 N86Y
(in brackets if different) proportions are based on successful
amplifications from 320 (319), 153 (157), 167 (168), 113 and 104
patients. There was no significant change of pfcrt 76T (OR 1.05,
95%CI; 0.94–1.16 p=0.39), pfcrt 76K (OR 0.98; 95%CI, 0.88–
1.11, p=0.79), pfmdr1 86Y (OR 0.92, 95%CI; 0.83–1.01 p=0.08)
or pfmdr1 86N (OR 1.05, 95%CI; 0.94–1.16 p=0.43) proportions
between 2003–2007 (figure 3). The minimum and maximum
haplotype proportions were as follows: Pfcrt 76T, 23–29%. Pfcrt
76K,75–81%. Pfmdr1 86Y, 36–47%. Pfmdr1 86N, 69–79%.
Fluctuations in parasite densities during and between
seasons
During early high transmission season parasite densities were
higher compared to low transmission season irrespective of pfcrt
K76T haplotype. For P. falciparum with 76K only, parasite
densities during early high transmission season were also higher
than during late high transmission season while there was no
difference between late high and low transmission season. For P.
falciparum with 76T only, parasite densities were higher during
both early and late high transmission season compared to the low
transmission season. (Table 2).
Lower parasite densities were associated with pfcrt 76T
and pfmdr1 86Y
For children under the age of 10 years, the age adjusted median
parasite density (P.falciparum/ml) was lower when only P. falciparum
with pfcrt 76T (15254 [95% CI, 12737–17772]; n=164) compared
to only pfcrt 76K (18664 [95% CI, 16676–20653]; p=0.003;
Figure 3. Proportion of Pfcrt 76K and 76T and pfmdr1 86N and 86Y haplotypes amongst children presenting with uncomplicated P.
falciparum malaria from January 2002 to December 2007. T=pfcrt 76T, K=pfcrt 76K, Y=pfmdr1 86Y, N=pfmdr1 86N.
doi:10.1371/journal.pone.0006866.g003
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lower age adjusted median parasite density (16320 [95% CI,
13696–18944]; n=224) compared to pfmdr1 86N, (18880 [95%
CI, 16701–21059]; P=0.018; n=445). If the children over the
age of 10 years were included in the analyses the differences were
not significant but the trend the same. The median parasite density
was 1977 parasites per ml less in children with pfcrt 76T compared
to children with pfcrt 76K (p=0.13) and 1504 parasites per ml less
in children with pfmdr1 86Y compared to children with pfmdr1 86N
(p=0.11).
Association between pfcrt K76T haplotype proportions,
transmission rate and drug pressure (figure 4)
Through out the year the number of treatments and the
proportion of pfcrt 76T vary in a remarkably similar fashion. The
malaria incidence starts to increase between April and May just
before the rainy season whilst the pfcrt 76T haplotype proportion
start to increase approximately one month later. The malaria
incidence peaks in June whilst the pfcrt 76T proportion peaks one
month later.
The number of genotypes per infection by season
A total of 163 samples from one complete year July 2004 – June
2005 were analysed. Pfmsp1 and pfmsp2 genotypes were successfully
identified in 156/163 and 153/163 children, respectively (figure 5).
The mean number of clones during the high and low transmission
seasons were 1.96 [95% CI, 1.73–2.18] and 1.84 [95% CI, 1.47–
2.21], respectively. There were no significant seasonal changes.
The pfmsp1 genotype R033 was identified in 42/46 samples that
also carried pfmdr1 86N whilst only 4/46 R033 genotypes also had
the pfmdr1 86Y haplotype (p=0.01). No association was found
between pfmdr1 86Y or pfcrt 76K or 76T with any of K1, MAD,
Ro33, FC or IC genotypes.
Linkage disequilibrium
Parasites carrying pfcrt 76T were more likely to also carry pfmdr1
86Y (OR, 2.71 [95% CI, 1.99–3.67]; P,0.0001; n=951).
Parasites carrying pfcrt 76K were more likely to also carry pfmdr1
86N (OR, 3.40 [95% CI, 2.45–4.74]; P,0.0001; n=951). There
was no seasonal variation.
Discussion
We present continuously collected data from clinical trials with
the same basic inclusion criteria conducted between October 2002
and December 2007. The proportions of pfcrt 76K and 76T and
pfmdr1 86N and 86Y do not vary significantly between high and
low transmission season in Guinea-Bissau and the proportions
remained unchanged between 2003 and 2007.
The low and stable proportion of pfcrt 76T indicates that this
haplotype (and thus P. falciparum normally resistant to standard dose
CQ) does not have a selective advantage great enough to become the
dominant haplotype in Guinea-Bissau. We have previously shown
that double normal dose CQ has a 78% efficacy against P. falciparum
with pfcrt 76T in Guinea-Bissau [2]. We have also shown that the
standard total dose prescribed and commonly taken is approximately
3 times the normal dose (75 mgkg
21) divided into smaller doses over
5d a y s[ 5 ] .I ti st h e r e f o r el i k e l yt h a tP. falciparum with pfcrt 76T are
generally treated effectively in Guinea-Bissau. Much of the selective
advantage associated with pfcrt 76T during treatment with normal
dose CQ [2,14] is therefore lost unless absorption is poor or the
prescribed treatment discontinued. This most probably accounts for
the lack of cumulative increase of pfcrt 76T in Guinea-Bissau during
the high transmission season.
The small, temporary, but significant increase of pfcrt 76T during
the beginning of the high transmission season occursat the same time
as the number of treated children increases and approximately one
month after the malaria incidence increases. Pfcrt 76T is likely to
provide an advantage soon after treatment when CQ concentrations
are moderately high [15]. An increased number of treated children
will increase the chance of a new infection occurring in a child with a
moderatelyhighCQconcentration.Thislikelihoodwillalsoincreases
as the malaria incidence increases. Thus it is probable that the
increased pfcrt 76T proportionispartly caused byselectionofpfcrt 76T
in new infections due both to an increased incidence of malaria and
an increased number of treatments. However, the increased pfcrt 76T
proportion is also likelyto be partlydue to recrudescence. P. falciparum
usually recrudesce a few weeks after treatment [2] and the pfcrt 76T
proportion should therefore increase a few weeks after an increase in
malaria incidence, as it does. Despite this pfcrt 76T does not
accumulate over the whole season supporting our hypothesis that
only a fraction survive the high dose treatment used.
Monitoring prescription patterns in 2003–2004 showed that,
out of 26134 consultations, 17924 (69%) of children below the age
of 5 years were diagnosed with malaria while only 13% of these
presumptively treated children had microscopically verified
malaria [11]. Similar monitoring during 2007 and 2008 found
that 13310/34884 (38%, monthly range 30–43%, authors
unpublished data) of children (under 15 years) attending health
centres were treated for malaria though only 415/13310 (3.2%,
monthly range 0.4–8.9%, authors unpublished data) had micro-
scopically verified malaria. In practice, CQ is used for the
treatment of fever and the drug selective pressure is high all the
year round. There is therefore no period of low CQ pressure
during which pfcrt 76K has a distinct selective advantage as
described in The Gambia and Sudan [9,10]. This probably
explains the surprisingly stable pfcrt 76T and pfcrt 76K proportions
during the dry season.
Table 2. Median number of P. falciparum per ml whole blood
by season.
Samples analysed P. falciparum/ml
Median 95% CI P Number
All
January-April 13200 10965–15435 191
a
May - August 20833 19175–22491 ,0.0001 348
b
September - December 14800 14183–15417 0.16(,0.0001) 449
c
Pfcrt 76T
January-April 7600 1196–14004 37
May - August 20000 12093–27907 0.04 73
September - December 14400 11697–17103 0.05 (0.31) 83
Pfcrt 76K
January-April 14400 12392–16408 131
May - August 21053 16848–25258 0.003 256
September - December 15200 14087–16314 0.48 (0.003) 335
Includes 14
a,7
b and 13
c children for whom pfcrt K76T genotyping failed.
P values and confidence intervals were calculated by quantile regression (1000
repetitions).
P values in bold refer to differences compared to the low season January - April.
P values in brackets and italics refer to comparisons between seasons May-
August and September –December.
Data from mixed infections are not presented as the numbers are small (9, 12
and 18 per season).
doi:10.1371/journal.pone.0006866.t002
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parasite that first becomes tolerant and eventually resistant.
Tolerance is a long process during which parasites acquire
several genetic changes making them gradually more tolerant of
CQ, whereas a resistant parasite is unaffected by drug
exposure.[15]. Pfcrt 76T identifies a parasite that is very likely
to be resistant when normal dose CQ is used, also in Guinea-
Bissau [2,14]. However, the common use of more efficacious
high doses of CQ in Guinea-Bissau probably turns pfcrt 76T into
a marker of tolerance. But, as discussed previously, pfcrt 76T is
also associated with a loss of fitness. The probable explanation
for the low and stable pfcrt 76T proportions is therefore the loss
of fitness associated with pfcrt 76T that negates the advantage
76T provides when CQ concentrations are moderate. No
parasite with the ability to survive the high doses of CQ
routinely used has become established in Guinea-Bissau despite
‘‘tolerant’’ (pfcrt 76T) parasites existing since at least 1992 [4].
This suggests that development of further resistance is a difficult
step in line with predictions [16] and the long time it took for
CQ resistance to develop in the first place [17].
Mutations in pfmdr1 have been associated with substantial fitness
cost [18]. We therefore assessed parasite densities as a proxy
marker of fitness. Pfcrt 76T and pfmdr1 86Y were associated with
lower parasite densities suggesting a cost of fitness associated with
at least one of these haplotypes as they are linked. This supports
the fitness argument for why pfcrt 76T has reached fixation at a low
prevalence in Guinea-Bissau. Including children above the age of
10 gave similar but not significant results. Differences in immunity
might account for the age effect. However, the data should be
interpreted with caution as the age effect is difficult to explain and
because it is possible that pfcrt 76T identifies a more virulent
parasite causing children to go to the health centres earlier.
As in the Gambia [10], there was no seasonal variation of pfmdr1
86N or 86Y proportions, there was linkage disequilibrium between
pfmdr1 86Y and pfcrt 76T and no significant seasonal variation of
the mean number of genotypes. The mean number of genotypes
were lower in Guinea-Bissau suggesting less chance of sexual
recombination in mosquitoes, that should slow the pace of
resistance development [15].
As in The Gambia, we noted lower parasite densities during the
second half of the high transmission season compared to the first
half. This might be due to an enhanced malaria specific immunity.
The differences in seasonal parasite density pattern between pfcrt
76T and pfcrt 76K parasites is difficult to interpret and is possibly
due to small number of P. falciparum with pfcrt 76T (only 37) during
the low transmission season.
Figure 4. Monthly variation of pfcrt 76T proportion, monthly number of children with microscopy verified malaria and mean
monthly number of children treated for malaria. Hollow circles. Pfcrt 76T prevalences in samples collected between October 2002 and
December 2007. Black squares. The number of malaria cases (incidence) verified by microscopy in studies 2003 to 2007. Black triangles. The
mean number of malaria treatments each month over the 2 year period December 2006 to November 2008.
doi:10.1371/journal.pone.0006866.g004
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increase throughout the high transmission season and is low and
stable between 2003 and 2007. We suggest that this is due to the
use of a more efficacious dosage of CQ in Guinea-Bissau
combined with a loss of fitness associated with pfcrt 76T. These
factors largely remove the selective advantage that P. falciparum
with pfcrt 76T have when normal dose CQ is used. The results
therefore indicate that CQ can be an effective drug if dosed
differently. As CQ is cheap and accessible further research into
dosing strategies of CQ should be done.
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